About Epitopix

Epitopix is a privately held company based in Willmar, Minnesota, and is an affiliate of Vaxxinova. We hold a USDA Establishment License No. 365 for the manufacturing of veterinary biologicals. Our mission is to perform discovery, research and development, and manufacturing of technologies to improve animal health and food safety. Epitopix owns intellectual property rights to key technologies, including SRP® Technology, involving the production of highly efficacious and safe veterinary vaccines. We value key partnerships to assist in the marketing and distribution of USDA licensed products in the US and global animal health industries.

Epitopix discovers and develops original veterinary vaccines to improve animal health and food safety, building upon a foundation of proprietary SRP® technologies, in an environment that values scientific creativity.Epitopix Mission

Our Core Strengths

Microbiological expertise and capability for innovation

broad portfolio of patents and patent applications

large-scale manufacturing capability for SRP® Technology vaccines

practical approach to effective bacterial vaccine solutions for producers and veterinarians



Epitopix began as the laboratory service division of Willmar Poultry Company (WPC) in Willmar, Minnesota. During the 1980s, WPC began to seek innovative ways to improve the health of its turkey breeding stock. In order to combat Salmonella, E. coli, Pasteurella (fowl cholera), and Hemorrhagic Enteritis virus, WPC created a USDA licensed vaccine laboratory, and selected a premier team of scientists to pioneer novel vaccine technology. This team pursued a single vaccine that would prevent as many as 30 different serotypes of Salmonella commonly found in the production of poultry and livestock.

Through many years of research, the team developed ground-breaking technology in the form of Siderophore Receptor and Porin (SRP) vaccines. This revolutionary vaccine immunizes against bacterial infections utilizing a cell-free purified extract of SRP proteins. By 1997, vaccine made from the combined SRP of Salmonella, E. coli, and P. multocida was in widespread use across the WPC breeder operations in Minnesota.


Epitopix, LLC was formed in 2002 to commercialize SRP Technology, and to discover new vaccine technologies that improve animal health and human food safety. Discovery and development continues today, to bring novel vaccine products to additional markets including livestock, poultry, and companion animals. Epitopix owns intellectual property rights to all of its discoveries and has out-licensed SRP Technology development rights for human medical applications to Syntiron, LLC.